Drugs / Tariquidar
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03809234 | May 2019 → Nov 2020 | neuropathy, painful | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1 | NCT00011414 | Feb 2001 → Nov 2007 | Wilms tumor, adrenal cortex carcinoma, refractory malignant neoplasm, sarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00001944 | Dec 1999 → Jun 2001 | breast cancer, lung cancer, ovarian cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04603066 | Jan 2021 → Oct 2023 | neuropathy, painful | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT00082368 | May 2004 → Apr 2014 | cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00071058 | Oct 2003 → Nov 2009 | adrenal cortex neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00069160 | Sep 2003 → Dec 2009 | kidney neoplasm, lung neoplasm, ovarian neoplasm, uterine cervix neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00048633 | Nov 2001 → Jun 2003 | breast neoplasm | QLT Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00042302 | Jun 2002 → Jul 2003 | non-small cell lung carcinoma | QLT Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00042315 | Jun 2002 → Jun 2003 | non-small cell lung carcinoma | QLT Inc. | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tariquidar | “Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors” NCT00011414 ↗8“Tariquidar (XR9576), a Selective MDR-1 Inhibitor” NCT00048633 ↗ “XR9576 (Tariquidar)” NCT00071058 ↗ |
| Known as | [11C]-Tariquidar | ChEMBL registry synonym — accepted as the source's own label CHEMBL348475 ↗ |
| Known as | XR9576 | “Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors” NCT00011414 ↗ |
| Action | Inhibit | “an experimental drug called XR9576, has blocked pumping by this protein” NCT00001944 ↗1“P-glycoprotein 1 inhibitor” CHEMBL348475 ↗ |
| Modality | Small molecule | — CHEMBL348475 ↗ |
| Route | Intravenous | “a 30-minute infusion of XR9576 intravenously (through a vein)” NCT00001944 ↗ |
| Target | ABCB1 | “P-glycoprotein 1 inhibitor” CHEMBL348475 ↗ |